NEW YORK, NY--(Marketwire -06/07/12)- Immunovative Inc. ("Immunovative") (IMUN) today announced that Dr. Michael Har-Noy, Founder and Chief Executive Officer of Immunovative Therapies, Ltd. ("ITL"), has been invited to lecture at the Division of Hematology/Oncology and the Robert H. Lurie Comprehensive Cancer Center's Grand Rounds on Friday, June 8, 2012. Grand Rounds are from 8-9 a.m. at the Robert H. Lurie Medical Research Center, 303 E. Superior, Gray Conference Room, Chicago, IL. Dr. Har-Noy will be discussing the latest developments in the field of immunotherapy of cancer and presenting data from Phase I/II clinical trials of AlloStim™. ITl is developing a new class of immunotherapy drugs designed to harness the power of the immune system to treat cancer, has 11 U.S. patents granted, 17 U.S. patents pending and 26 corresponding applications pending internationally and has two experimental product candidates for the treatment of cancer in clinical development: AlloStim™ and AlloVax™.
The Lurie Comprehensive Cancer Center, designated by the National Cancer Institute as a comprehensive cancer center, is the focus of cancer research, treatment, and education at Northwestern University. The center coordinates the University's cancer and cancer-related activities and brings together more than 250 basic scientists, clinical investigators, and educators from throughout the McGaw Medical Center.
Northwestern University School of Medicine in Chicago, IL is a world-renowned cancer research facility where faculty, fellows, postdocs and students and staff study some of the most exciting problems in cancer treatments and technology today.
Grand rounds are an integral part of medical education. Grand rounds help doctors and other healthcare professionals keep up to date in important evolving areas by presenting the newest research and treatments in an area.
About Immunovative Inc.
About Immunovative, Inc.: On December 15, 2011, Immunovative, Inc. ("IMUN") signed an exclusive License Agreement (the "License Agreement") with Immunovative Therapies, Ltd ("ITL"). Under the terms of the License Agreement, IMUN has been granted an exclusive, worldwide license to commercialize any products covered under ITL's current issued and pending patent application portfolio, as well as the rights to any future patent applications, including improvements or modifications to the existing applications and any corresponding improvements or new versions of the existing products including.
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israel Office of the Chief Scientist. Immunovative is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israel technological incubator program. The company was the Misgav Venture Accelerator's candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. Immunovative Therapies Ltd specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease. Please visit Immunovative's website at: www.immunovative.co.il
DISCLAIMER Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on IMUN's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which IMUN has little or no control. Such forward-looking statements are made only as of the date of this release, and IMUN assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by IMUN with the Securities and Exchange Commission.
Mr. Antonio Treminio
Chairman & Chief Executive Officer
New York: +1-212-315-9705
Email: Email Contact
Dr. Michael Har-Noy
Founder & Chief Executive Officer
Immunovative Therapies, Ltd.
Israel Tel: +972-2-6506288
US Tel: +1-760-444-9040
Email: Email Contact